AXT914   Click here for help

GtoPdb Ligand ID: 10696

Synonyms: AXT-914 | PD127836
Compound class: Synthetic organic
Comment: AXT914 is a calcium-sensing receptor (CaSR) modulator that was developed by Novartis as a small molecule calcilytic [1]. It is structurally related to the CaSR negative allosteric modulator (NAM) ATF936, but exhibits better solubility properties in microemulsion formulations. AXT914 acts to promote a rapid and transient release of parathyroid hormone. CaSR antagonists/NAMs are being investigated as bone-forming osteoporosis therapeutics.

Note that this entry was updated in March 2024, with reference to the chemical structure provided in [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 0
Rotatable bonds 6
Topological polar surface area 41.9
Molecular weight 487.39
XLogP 4.36
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C#CCOC1=CC2=C(C=C1)N(CC3=CC=C(C=C3)Br)C(=O)N=C2C4=CC=C(C=C4)C(C)C
Isomeric SMILES CC(C)C1=CC=C(C=C1)C2=NC(=O)N(CC3=CC=C(Br)C=C3)C4=CC=C(OCC#C)C=C24
InChI InChI=1S/C27H23BrN2O2/c1-4-15-32-23-13-14-25-24(16-23)26(21-9-7-20(8-10-21)18(2)3)29-27(31)30(25)17-19-5-11-22(28)12-6-19/h1,5-14,16,18H,15,17H2,2-3H3
InChI Key KIZITKARUSPCHY-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
AXT914 completed Phase 1 evaluation [1]. This study found little evidence of improvement in bone-formation markers, and when combined with ATX914 dose-related hypercalcaemia the decision was made to discontinue this clinical program.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00417261 Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects. Phase 1 Interventional Novartis AXT914-induced PTH release was rapid and transient in human subjects but did not translate into a bone anabolic response. 1